Can PI3K Inhibitors Reduce Endocrine Therapy Resistance in Early Breast Cancer?

The new phase II LORELEI trial tested whether the PI3K inhibitor taselisib could improve response rates when added to letrozole in the neoadjuvant setting.

Source: CancerNetwork - August 28, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news